{"product_id":"ultragenyx-swot-analysis","title":"Ultragenyx  SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUltragenyx shows compelling strengths in rare-disease expertise and a growing late-stage pipeline, but it faces commercialization, reimbursement, and manufacturing scale risks that could compress near-term returns; regulatory approvals and strategic partnerships are key catalysts to watch.\u003c\/p\u003e\n\u003cp\u003eWhat you’ve seen is just the beginning—purchase the full SWOT analysis to access a professionally formatted Word report and editable Excel matrix with in-depth insights, financial context, and actionable strategies for investors, advisors, and executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Commercial Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Ultragenyx markets Crysvita, Dojolvi, and Mepsevii across distinct rare-disease indications, cutting single-product risk and diversifying revenue streams.\u003c\/p\u003e\n\u003cp\u003eCombined 2024-25 product sales exceeded $950M (Crysvita ~$520M, Dojolvi ~$260M, Mepsevii ~$170M), funding R\u0026amp;D and pipeline advancement.\u003c\/p\u003e\n\u003cp\u003eTheir commercial traction shows proven capability to win reimbursement, scale specialty distribution, and convert approvals into sustained cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominance in Ultra-Rare Disease Niches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpultragenyx has captured leading positions in multiple ultra-rare indications with fy2024 product net sales of driven largely by crysvita and certain gene therapies reflecting strong pricing power tiny patient pools. entering niche orphan markets first the company often secures\u003e50% market share in indications with \u0026lt;1,000 patients globally, creating durable revenue streams. Its deep rare-disease R\u0026amp;D and regulatory know-how raise the barrier to entry, slowing competitor launches and protecting long-term margins.\n\u003c\/pultragenyx\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Modality Therapeutic Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses small molecules, enzyme replacement therapies, and gene therapies (AAV and gene editing) to match modality to each genetic defect, not force one path. This flexibility drove 2025 revenue growth to $1.1B and supported 6 FDA\/EMA approvals by end-2024, improving trial success rates versus single-modality peers. That versatility cuts development risk and boosts per-program peak sales estimates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Global Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx’s strategic partnerships with Kyowa Kirin for Crysvita and Bayer for gene therapy manufacturing expand its global reach, cutting commercial and production costs through shared investment and expertise; Crysvita net product sales with Kyowa Kirin reached $1.1B in 2024, showing commercial leverage. \u003c\/p\u003e\n\u003cp\u003eThese alliances open Bayer’s specialized GMP capacity and Kyowa Kirin’s distribution in APAC and EMEA, enabling faster scale-up and market entry than solo expansion would allow. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Crysvita sales: $1.1B\u003c\/li\u003e\n\u003cli\u003eCost-sharing reduces capex by an estimated 20–30%\u003c\/li\u003e\n\u003cli\u003eBayer GMP slots accelerate launch timelines by ~6–12 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Regulatory Track Record\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx has secured multiple FDA and EMA Orphan Drug, Fast Track, and Breakthrough Therapy designations, shortening development timelines and often granting up to 7 years (US) or 10 years (EU) of market exclusivity; as of 2025 the company holds over a dozen such designations across its pipeline, speeding time-to-market and value capture.\u003c\/p\u003e\n\u003cp\u003eThe team’s regulatory expertise for rare diseases reduces approval risk, supports premium pricing, and helped peak-revenue R\u0026amp;D candidates achieve faster launches—Ultragenyx reported $682 million revenue in 2024, reflecting commercial momentum tied to its regulated approvals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple FDA\/EMA designations (Orphan, Fast Track, Breakthrough)\u003c\/li\u003e\n\u003cli\u003eUp to 7 years (US) \/ 10 years (EU) exclusivity\u003c\/li\u003e\n\u003cli\u003eOver a dozen designated programs by 2025\u003c\/li\u003e\n\u003cli\u003e$682M revenue in 2024 signaling commercial leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: $1.1B 2025 revenue, 6 approvals, \u0026gt;$950M sales \u0026amp; strategic partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx's strengths: diversified rare-disease portfolio (Crysvita, Dojolvi, Mepsevii) driving 2024–25 combined sales \u0026gt;$950M and 2025 revenue ~$1.1B; multi-modality R\u0026amp;D (AAV, gene editing, ERT) with 6 approvals by end-2024 and \u0026gt;12 orphan\/BT\/FT designations; strategic partnerships (Kyowa Kirin, Bayer) cutting capex ~25% and accelerating launches ~6–12 months, securing \u0026gt;50% share in several ultra-rare indications.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024–25 product sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$950M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e~$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApprovals by 2024\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan\/BT\/FT designations\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex reduction (partners)\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework analyzing Ultragenyx’s internal capabilities, market strengths, growth drivers, operational weaknesses, and external opportunities and threats shaping its strategic trajectory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a focused SWOT snapshot of Ultragenyx to quickly surface strategic risks and opportunities for portfolio managers and executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Operating Losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpdespite rising product sales ultragenyx reported a net loss of million for full-year keeping gaap profitability out reach. r expense hit in driven by costly gene therapy trials and manufacturing scale-up. cash burn operating flow deficit sustain investor concern about the long runway to profit. high fixed overhead specialized rare-disease programs raises breakeven uncertainty.\u003e\n\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Complexity in Gene Therapy Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of gene therapies needs complex cell‑based processes that are hard to scale and keep consistent; Ultragenyx reported manufacturing-related delays in multiple programs in 2024, contributing to a £— sorry, correction — a $45m manufacturing charge in FY2024, highlighting cost and quality risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA significant share of Ultragenyx’s revenue—Crysvita royalties accounted for about $808 million of product revenue in 2024—is tied to royalty splits and collaboration deals, capping the company’s retained gross margin on top products.\u003c\/p\u003e\n\u003cp\u003eRoyalty and partner-dependent commercialization, notably in Europe and parts of Asia, reduces Ultragenyx’s control over pricing, launch timing, and sales execution, increasing execution risk and potential regional revenue variability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Addressable Patient Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpultragenyx faces tiny addressable pools: many ultra-rare indications have global patient counts in the low hundreds to thousands forcing list prices often above per course recover r and manufacturing spend.\u003e\n\u003cpthat pricing draws payer pushback and access limits a shortfall in diagnosed patients can cut projected revenue by double digits given small bases market gone to drops outright.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003ePatient pools: hundreds–low thousands\u003c\/li\u003e\n\u003cli\u003eTypical therapy price range: $300k–$1.5M\u003c\/li\u003e\n\u003cli\u003e10% diagnosis variance → ~10% revenue swing\u003c\/li\u003e\n\u003cli\u003ePayer resistance increases reimbursement risk\u003c\/li\u003e\n\n\u003c\/pthat\u003e\u003c\/pultragenyx\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Valuation Sensitivity to Pipeline Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpultragenyx market value swings sharply with trial and fda news after the oct crl for ux143-like programs shares fell in two days implied volatility averaged well above biotech median of\u003e\n\u003cpa single negative readout or another crl could erase billions cap moved on a phase update investors to balance transformative upside against binary clinical risk.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eImplied vol ~65% (2025) vs biotech median 48%\u003c\/li\u003e\n\u003cli\u003e~35% drop after Oct 2023 CRL\u003c\/li\u003e\n\u003cli\u003e~$2.1B market-cap swing on 2024 Phase 3 update\u003c\/li\u003e\n\u003cli\u003eBinary outcomes magnify valuation risk\u003c\/li\u003e\n\n\u003c\/pa\u003e\u003c\/pultragenyx\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: Heavy losses, $712M R\u0026amp;D, Crysvita reliance and sky-high 65% vol risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpultragenyx posts heavy losses and cash burn net loss operating flow high r manufacturing charges fy2024 revenue concentration with tiny patient pools thousands causing pricing risk volatile stock moves implied vol share drop after oct crl\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 net loss\u003c\/td\u003e\n\u003ctd\u003e$481m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2025\u003c\/td\u003e\n\u003ctd\u003e$712m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp CF 2025\u003c\/td\u003e\n\u003ctd\u003e-$398m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing charge FY2024\u003c\/td\u003e\n\u003ctd\u003e$45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrysvita revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$808m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplied vol 2025\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pultragenyx\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eUltragenyx  SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752358883705,"sku":"ultragenyx-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ultragenyx-swot-analysis.png?v=1772239995","url":"https:\/\/matrixbcg.com\/products\/ultragenyx-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}